Evofem amends prior 8-K to fix exhibit link for Series F-1 Preferred Stock certificate

Evofem Biosciences, Inc.

Filing corrects reference to Certificate of Designation of Series F-1 Preferred Stock.
Original merger agreement with Aditxt reported on Dec 27, 2023 remains unchanged.
No financial impact or change to merger terms from this technical amendment.
Exhibit 3.1 now properly incorporated by reference to Dec 12, 2023 8-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.